Premium
Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon‐Scanning Method
Author(s) -
Dotson W D,
Douglas M P,
Kolor K,
Stewart A C,
Bowen M S,
Gwinn M,
Wulf A,
Anders H M,
Chang C Q,
Clyne M,
Lam T K,
Schully S D,
Marrone M,
Feero W G,
Khoury M J
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.226
Subject(s) - action (physics) , interim , pharmacogenomics , computer science , process (computing) , genomic sequencing , time horizon , computational biology , data science , microbiology and biotechnology , biology , bioinformatics , mathematics , genetics , genome , mathematical optimization , geography , gene , physics , archaeology , quantum mechanics , operating system
As evidence accumulates on the use of genomic tests and other health‐related applications of genomic technologies, decision makers may increasingly seek support in identifying which applications have sufficiently robust evidence to suggest they might be considered for action. As an interim working process to provide such support, we developed a horizon‐scanning method that assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate an application of the method to pharmacogenomics tests. Clinical Pharmacology & Therapeutics (2014); 95 4, 394–402. doi: 10.1038/clpt.2013.226